相关实验视频

Updated: Jul 4, 2025

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics

Published on: March 15, 2024

PTC596诱导的BMI-1抑制通过诱导铁亡来对抗神经母细胞瘤的多药性耐药性

Giulia Elda Valenti¹, Antonella Roveri², Rina Venerando²

¹Department of Experimental Medicine, General Pathology Section, University of Genoa, 16132 Genoa, Italy.

Antioxidants (Basel, Switzerland)

|January 26, 2024

概括

这项研究探讨了针对多抗药性神经母细胞瘤的新策略. 一种BMI-1抑制剂PTC596有效地杀死了耐药细胞并诱导了铁亡,为化学抵抗提供了一种有前途的方法.

科学领域:

在瘤学瘤学.
癌症生物学癌症生物学
药理学药理学是指药理学的学科.

背景情况:

神经母细胞瘤 (NB) 呈现出显著的异质性,高风险的形式往往导致复发和耐药性.
标准化疗会诱导氧化应激,但可以增强NB细胞中的抗氧化反应,从而导致化学抵抗.
多抗药性 (MDR) NB细胞的特征是高谷氨 (GSH),BMI-1过度表达,以及突变的P53.

研究的目的:

研究一种新的策略,以克服多药耐药神经母细胞细胞中的化学抵抗.
在MDR NB模型中评估BMI-1抑制剂PTC596和突变P53活性剂PRIMA-1^MET的疗效.

主要方法:

使用了多抗药 (MDR) 神经母细胞瘤 (NB) 细胞的体外模型.
评估了PTC596和PRIMA-1^MET对MDR NB细胞活性的细胞毒性影响.
分析了这些化合物对表皮层-介质细胞转换 (EMT) 蛋白,克隆基因潜力和癌症干性的影响.
测量了GSH水平,过氧化物生产,脂质过氧化和诱导的铁亡.

主要成果:

PTC596对MDR NB细胞表现出显著的细胞毒性,而PRIMA-1^MET对细胞活力没有影响.
无论是PTC596还是PRIMA-1^MET都降低了EMT蛋白表达,克隆性潜力和MDR细胞中的癌症干细胞.
PTC596,单独或组合,降低了GSH水平,增加了过氧化和脂质过氧化,并诱导了铁亡.

结论:

通过抑制BMI-1,PTC596显示出对抗神经母细胞瘤化学抵抗的前景.
准BMI-1并诱导铁亡是一种对抗药物神经母细胞瘤的潜在治疗策略.

关键词:

这就是为什么BMI-1是BMI-1.在P53中,P53是P53 铁性化 (ferroptosis) 是一种葡萄糖氨酸氨酸是什么?多种药物耐药性多种药物耐药性神经母细胞瘤的神经母细胞瘤

更多相关视频

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

相关概念视频

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...